Intellia Therapeutics: Board of Directors Takes Advantage of Stock Plunge for a $1.4 Million Stock Purchase

Intellia Therapeutics (NTLA) positions itself in the field of CRISPR/Cas9 technology to directly cure diseases at their genetic origin. The company focuses on developing so-called in-vivo therapies, where the gene-editing tool is injected directly into the patient's body to make permanent changes to the genetic material. The main goal is to provide a "single-dose" solution – a one-time treatment that eliminates the need for lifelong medication or regular infusions. Current key solutions for patients include Nexiguran-Ziclumeran (Nex-z) for the...